Glucagon is known to affect glomerular filtration rate and renal tubular solute and fluid transport, although it is only thought to act directly on the thick ascending limb (TAL) and collecting duct (CD). Indeed, previous studies have detected glucagon-sensitive adenylate cyclase exclusively in these nephron segments, suggesting the presence of glucagon receptors. In the present study, we have demonstrated for the first time that glucagon receptor mRNA is expressed in the rat proximal tubule, as well as in the TAL and CD. By autoradiography, we have also shown that specific binding of glucagon occurs in both the renal cortex and medulla. In addition, using proximal tubule brush-border membrane (BBM) vesicles for studies of glucose transport, we have established that glucagon stimulates glucose uptake via a facilitative GLUTmediated transport process (by 58 % ; P 0.005), whereas cAMP stimulates only the sodium glucose-linked transporter (' SGLT ')-mediated glucose uptake (by 53 % ; P 0.05). Taken together, these findings suggest that glucagon could have a role in controlling proximal tubular transport function, including glucose reabsorption, but unlike in the TAL and CD, the proximal tubule glucagon receptor might not be coupled primarily to adenylate cyclase.
INTRODUCTION
Circulating glucagon has been linked to the increase in glomerular filtration rate and renal blood flow following a protein-rich meal, to refeeding natriuresis following starvation [1] , and to increases in phosphate excretion [2] . These effects of glucagon may be due to a direct action on the glomerulus and proximal tubule, but they might also be indirect, mediated by the hepatic release of circulating cAMP [3] [4] [5] . In contrast, the effects of glucagon on calcium, magnesium and proton transport in the thick ascending limb (TAL) and col-lecting duct (CD) are the result of a direct stimulation of glucagon receptors coupled to adenylate cyclase and cAMP generation [4, [6] [7] [8] . However, although glucagon can be shown to inhibit sodium and phosphate reabsorption along the proximal tubule [9] , there is still no evidence for a direct action on this nephron segment, or for the presence of glucagon-sensitive adenylate cyclase.
Studies using intestinal enterocytes, where the process of glucose transport is very similar to that in the proximal tubule, suggest that increased secretion of pancreatic glucagon in experimental diabetes may be responsible for the enhanced sodium glucose-linked transporter (SGLT)-mediated glucose uptake that occurs across the brush-border membrane (BBM) [10] ; a response that is cAMP-dependent [11] . Such findings in the small intestine raise the question of whether glucagon might also regulate renal glucose transport. Thus the main purpose of our present study was to determine if mRNA for the glucagon receptor is expressed along the proximal tubule, as well as in more distal nephron segments. In addition, in vitro receptor autoradiography was used to determine the binding properties of radiolabelled glucagon in the normal rat renal cortex and medulla. Finally, to determine the effect of glucagon on renal glucose transport and the specific BBM transporters involved, we also measured the Na + -dependent (SGLT) and facilitative (GLUT) components of glucose transport across BBM vesicles prepared from proximal tubules exposed to glucagon or cAMP.
METHODS

Animals
The study used 230-260 g male Sprague-Dawley rats allowed ad libitum access to a standard rat chow and water. Animals were anaesthetized by intraperitoneal administration of sodium pentobarbitone (90 mg\kg ; Sagatal ; Rhone-Merieux, Harlow, Essex, U.K.) before removal of their kidneys. All procedures were carried out in accordance with the Animals (Scientific Procedures) Act 1986.
Reverse transcription (RT)-PCR
The abdominal aorta of anaesthetized animals was cannulated and the left kidney perfused with microdissection solution [sterile Hanks-balanced salt solution (Sigma, Poole, Dorset, U.K.) supplemented with 1 mmol\l MgCl # , 1 mmol\l sodium acetate, 1 mmol\l lactic acid, 1 mmol\l sodium pyruvate, 1 mmol\l glutamine, 20 mmol\l Hepes and 0.1 % protease-free BSA (pH 7.5)], followed by perfusion with the same solution containing 0.24 % (w\v) collagenase (0.32 units\mg ; Boehringer Mannheim, Lewes, East Sussex, U.K.). Kidneys were rapidly excised, decapsulated and sliced into thin corticomedullary pyramids, which were incubated at 37 mC for 15 min in microdissection solution containing 0.15 % (w\v) collagenase gassed with air\CO # (19 : 1, v\v). After incubation, the pyramids were placed in collagenase-free solution and microdissection performed at 4 mC under sterile conditions in accordance with anatomical and morphological criteria [12] . Pools of glomeruli or identical cortical tubular segments (5-30 mm) were transferred to sterile slides coated with 0.05 % BSA and photographed to allow estimation of tubular length. RNA was extracted from identical pools of microdissected nephron segments using an adapted guanidinum thiocyanate-phenol-chloroform method [13] . Following extraction, RNA was resuspended in storage buffer [10 mmol\l Tris\HCl (pH 7.6), 1 mmol\l EDTA, 2 mmol\l dithiothreitol and 40 units\ml RNasin2] to 3 µl\mm of tubule length and stored at k80 mC until use. Gene expression was measured by RT-PCR using specific intron-spanning primers designed from the published sequence of rat glucagon receptor (GenBank2 accession number U63021 ; forward primer position 4527-4548, reverse position 5396-5416) and β-actin (GenBank2 accession number V01 217 ; forward position 2170-2194, reverse position 3055-3079). For each nephron segment, 10 µl of RNA was reversetranscribed with 0.5 µg of oligo-dT 12-18 primer and a First Strand cDNA Synthesis kit (Superscript II RNase H − reverse transcriptase ; Life Technologies, Paisley, Renfrewshire, Scotland, U.K.). PCR was carried out on 10 % of the cDNA product (corresponding to approx. 0.5 mm of tubule) using a PCR Core System I kit (Promega, Southampton, U.K.). cDNA volumes were adjusted to establish consistent β-actin levels between samples prior to PCR for glucagon receptor. For each reaction, denaturation at 95 mC for 3 min was followed by 33 cycles for glucagon receptor or 25 cycles for β-actin at 95 mC for 30 s, 65 mC or 58 mC for 1 min for β-actin or glucagon receptor respectively, and 72 mC for 1 min. The reaction was completed by a final 5 min extension stage at 72 mC. PCR products were resolved on a 2 % (w\v) agarose gel containing ethidium bromide. Bands were visualized using a Multimager (Bio-Rad Laboratories, Hemel Hempstead, Herts., U.K.). PCR products were sequenced by the Oswel DNA Sequencing Laboratory (University of Southampton, U.K.).
Autoradiography
Excised kidneys were decapsulated, embedded in OCT compound (BDH, Poole, Dorset, U.K.) and frozen in isopentane precooled in liquid nitrogen. Serial 10 µm cryostat sections (cut at k20 mC) were thaw-mounted on to polysine-coated slides (BDH) and air-dried for 1 h. Slides were preincubated for 15 min at 20 mC in 100 mmol\l Hepes (pH 7.8) containing 30 mmol\l KCl to reduce the levels of endogenous hormone. This was followed by a 2 h incubation at 20 mC in buffer containing 100 mmol\l Hepes, 120 mmol\l NaCl, 1.2 mmol\l MgSO % , 2.5 mmol\l KCl, 15 mmol\l sodium acetate, 10 mmol\l glucose, 1 mmol\l EDTA, 1 g\l BSA, 0.025 % Bacitracin, 100i10' international units\l aprotinin and "#&I-labelled glucagon (ranging from 1.5-1000 pmol\l).
Non-specific binding was established by incubating alternate slides in the presence of 1 µmol\l unlabelled glucagon. The reaction was terminated using three 2 min washes in ice-cold 100 mmol\l PBS (pH 7.4). Sections were dried in a stream of cold air, followed by air-drying overnight. Slides were then exposed to $H hyperfilm (Amersham Biosciences, Little Chalfont, Bucks., U.K.) for 7 days at 4 mC. Films were developed in Kodak D19, followed by fixation in Hypam (Ilford, Moberly, Cheshire, U.K.), and the binding density determined in the cortex and medulla using a GS-700 imaging densitometer (Bio-Rad Laboratories). Specific binding was determined by subtracting the density obtained in the presence of unlabelled glucagon (non-specific binding) from that obtained during incubation with "#&I-labelled glucagon alone (total binding). Values were expressed as arbitrary units\mm#. For high-resolution localization studies, autoradiography was performed as described above using 500 pmol\l "#&I-labelled glucagon and 500 nmol\l unlabelled glucagon for total and non-specific binding respectively. Prior to incubation with glucagon, the sections were probed with Vector Red (Vector Labs Ltd, Peterborough, U.K.) to stain for endogenous alkaline phosphatase. Following drying overnight, the slides were dipped in molten nuclear emulsion (K2 ; Ilford) and stored in the dark for 4 days at 4 mC. Slides were developed and fixed as described above, and photographed using a KS300 imaging system (Imaging Associates Ltd, Oxford, U.K.).
BBM vesicles
Excised kidneys were transferred to ice-cold saline and then placed individually on to an ice-cold surface to allow dissection of the cortex. Cortical fragments from six kidneys were pooled and then divided into two equal aliquots. These were subsequently lightly homogenized in 30 ml of buffer containing 300 mmol\l mannitol, 5 mmol\l EGTA and 12 mmol\l Tris\HCl (pH 7.4) using 6 strokes of a hand-held glass Teflon homogenizer. Paired incubations were carried out by adding 10 nmol\l glucagon or 2 mmol\l dibutyryl cAMP in the presence of 1 mmol\l 3-isobutyl-1-methylxanthine (inhibits phosphodiesterase) to one suspension, the other receiving the vehicle only as control. Suspensions were then incubated at 37 mC in a shaking water bath, whilst being gassed with 100 % O # . After 30 min, tubules were separated by centrifugation (2 min at 40 g) and BBM prepared from the precipitate using the standard double-magnesium precipitation method [14] . The final pellet of BBM vesicles was resuspended to give a protein concentration of 3-6 mg\ml. The concentration of protein [15] and activities of alkaline phosphatase [16] and Na + \K + -ATPase [17] in the initial homogenate and BBM preparation were determined to derive values for enrichment of these marker enzymes.
Uptake studies were carried out at 20 mC on freshly prepared vesicles [10] . Briefly, the transport process was initiated by mixing equal volumes of vesicle suspension and uptake buffer (200 mmol\l sodium thiocyanate, 20 mmol\l Hepes and 0.1 mmol\l MgSO % containing D-[$H]glucose, such that the final concentration of glucose was 30-960 µmol\l). Uptake was terminated after 4 s by the addition of 3 ml of 154 mmol\l NaCl containing 0.5 mmol\l phlorizin, followed by vacuum filtration through 0.45 µm nitrocellulose filters (Sartorius, Go$ ttingen, Germany). Three further washes were carried out. Parallel uptakes using uptake buffer containing 1 mmol\l phlorizin to block SGLT-mediated transport showed that uptake was 96 % phlorizin-sensitive. In order to assess GLUT-mediated transport, a higher glucose concentration (20 mmol\l) was used in the presence of 1 mmol\l phlorizin, a value in keeping with the low-affinity of GLUT transporters for glucose [18] . GLUT-mediated transport was taken as phlorizininsensitive uptake, since passive (L-[$H]glucose) transport measured at 20 mmol\l glucose contributed 1% to phlorizin-insensitive transport (0.02 nmol\mg of protein per 4 s). Glucose accumulation was estimated from scintillation counting of the filters and expressed as nmol\mg of protein per 4 s. The kinetic parameters of V max (maximum transport capacity) and K t (glucose concentration at half V max ) for phlorizin-sensitive uptake were derived using a non-linear least-squares curvefitting program.
Statistics
Values are expressed as meanspS.E.M. ; n values represent the number of experiments per treatment group. Differences between groups were assessed by paired Student's t test and considered significant at P 0.05.
RESULTS
As anticipated, RT-PCR of defined nephron segments revealed that glucagon receptor mRNA expression is abundant in the distal portions of the nephron (Figure 1) . However, the mRNA for this receptor was also detected in the glomerulus, proximal convoluted tubule (PCT) and straight tubule segments (Figure 1) . Sequencing of the PCR products from the PCT and TAL demonstrated that the transcripts were identical ; therefore the low abundance in the PCT did not represent mispriming for a related receptor. Moreover, transcript sequences at the intron\exon boundaries revealed that alternative splice variation was not responsible for the detection of glucagon receptor mRNA expression in the PCT. Autoradiography using "#&I-labelled glucagon confirmed a high degree of specific binding in the medulla of control kidneys and also demonstrated specific binding in the outer cortex, although to a lesser degree than in the medulla (Figure 2) . In both the cortex and medulla, nonspecific binding represented approx. 40 % of the total binding at "#&I-labelled glucagon concentrations ranging from 60-1000 pmol\l ; however, at lower concentrations, non-specific binding accounted for almost 90 % of total binding (results not shown). Studies to determine the localization of "#&I-labelled glucagon binding employed Vector Red to stain for endogenous alkaline phosphatase, a marker of the BBM, which allows specific identification of proximal tubules. Total binding in the outer cortex was apparent in all nephron segments, including those that were positively stained for alkaline phosphatase ( Figure 3A) . Specific binding was apparent throughout the PCT, but was particularly evident at the BBM. Nonspecific binding was considerably lower in all nephron regions ( Figure 3B ), including the proximal tubule, demonstrating the presence of specific glucagon-binding sites in this nephron region.
Glucose-uptake experiments displayed a characteristic time-dependent overshoot, which was inhibited by phlorizin (Figure 4) , the remaining component being a mixture of facilitated and passive (non-carrier-mediated) transport. Since the overshoot demonstrated that glucose uptake was linear up to 10 s, a time point of 4 s was used for uptake experiments comparing the effects of glucagon and cAMP. Passive transport was measured using L-[$H]glucose and was shown to contribute 1% to phlorizin-insensitive transport (0.02 nmol\mg of protein per 4 s). Incubation with glucagon or cAMP did not affect the enrichment of alkaline phosphatase (control, Uptake was measured at 20 mC using buffer containing 110 mmol/l sodium thiocyanate and 100 µmol/l D- [ 3 H]glucose in the absence or presence of 1 mmol/l phlorizin (PZ) to block SGLT-mediated transport.
6.95p2.0-fold versus experimental, 6.68p2.1-fold ; n l 12, P l 0.73) or Na + \K + -ATPase (control, 0.79p0.15-fold versus experimental, 0.72p0.19-fold ; n l 12, P l 0.77). Vesicle-trapped space, as determined by incubation of BBM vesicles with 100 µmol\l D-[$H]glucose for 15 min, was also unaffected by treatment (2.55p0.25-fold versus 2.25p0.17-fold ; n l 12, P l 0.38). Incubation of cortical tubules with glucagon promoted GLUT-mediated glucose transport across the BBM by 58 % compared with control (1.91p0.2 versus 3.03p 0.2 nmol\mg of protein per 4 s ; n l 6, P 0.005), where GLUT-mediated transport is uptake at 20 mmol\l glucose in the presence of 1 mmol\l phlorizin. However, glucagon had no effect on the V max of SGLT-mediated glucose transport (1.83p0.19 versus 2.21p0.33 nmol\ mg of protein per 4 s ; n l 6). In contrast, cAMP significantly increased the V max of SGLT-mediated transport by 53 % (2.56p0.39 versus 3.99p0.70 nmol\ mg of protein per 4 s ; n l 6, P 0.05), but had no effect on GLUT-mediated transport (2.71p0.21 versus 2.56p0.29 nmol\mg of protein per 4 s ; n l 6).
DISCUSSION
Our current findings are the first demonstration of the presence of glucagon receptor mRNA in defined nephron segments. In keeping with glucagon binding and functional studies carried out in the early 1980s [6, 8] , the mRNA for the glucagon receptor was abundant in the more distal parts of the nephron : the TAL and CDs. The data from our present study are significant in that glucagon receptor mRNA expression was also detected in the proximal tubule and specific "#&I-labelled glucagon binding was found in the outer cortex of whole kidney sections. High-resolution autoradiography demonstrated that specific binding in the cortex was, at least in part, due to glucagon-binding sites located along the proximal tubule. The latter experiments were done because a suitable antibody against the glucagon receptor was not available.
Acute exposure of cortical cells to glucagon promoted GLUT-mediated glucose transport only. Since glucose reabsorption occurs almost exclusively in the proximal tubule [19] , this implies a potential role for glucagon in the regulation of glucose transport. A concentration of 10 nmol\l glucagon was used in the present study, because it has been shown to maximally increase glucose transport [10] and cAMP generation [20] in intestinal enterocytes at concentrations ranging from 1-10 nmol\l. Additionally, glucagon is highly susceptible to protease action, so its actual concentration during incubation with renal cells is likely to be much lower than the initial concentration in the incubation fluid.
Our present results, together with the recent observation by Au et al. [21] that the structurally related enteric hormone glucagon-like peptide 2 (' GLP-2 ') can rapidly promote expression of the facilitative glucose transporter GLUT2 at the intestinal BBM, suggest that the glucagon family of peptide hormones is potentially important in the acute control of epithelial glucose transport. That these hormones can affect proximal tubular function more generally is also supported by a recent study of Moreno et al. [22] in which glucagon-like peptide-1 (' GLP-1 ') was shown to increase lithium clearance and sodium excretion in rats.
The classical model for glucose transport across renal and intestinal absorptive cells involves SGLT-mediated glucose uptake across the BBM, followed by exit across the basolateral membrane via facilitative GLUT-mediated transport. However, Kellet and Helliwell [23] found that a significant proportion of total BBM glucose transport during maximal sugar uptake across the intestinal epithelium is mediated by GLUT2. Furthermore, insertion of GLUT2 into the intestinal BBM is acutely regulated by protein kinase C (' PKC ') activity [24] . These observations may be relevant to the kidney, as we have shown previously [25] that a facilitative GLUTmediated component contributes to renal BBM glucose transport. Thus the finding that cAMP is involved in the regulation of SGLT-mediated uptake at the renal BBM, whereas glucagon increases GLUT-mediated uptake, suggests that glucagon receptors expressed in the proximal tubule are not coupled primarily to activation of adenylate cyclase. This interpretation would explain the failure to detect glucagon-sensitive adenylate cyclase activity in the proximal tubule [6] . Moreover, using cultured baby hamster kidney cells, it has been shown [26] that glucagon receptors can stimulate a second and independent G-protein-coupled pathway, activating phospholipase C and releasing intracellular Ca# + from inositol trisphosphate (' IP3 ')-sensitive Ca# + stores. Wakelam et al. [27] have also found evidence for this alternative signalling pathway in cultured hepatocytes.
In summary, in the present study, we have shown that glucagon receptor mRNA and specific glucagon-binding sites are present in the renal proximal tubule, and that glucagon promotes GLUT-mediated glucose transport across the proximal tubule BBM. This is in contrast with its effect on glucose uptake across the intestinal BBM, which is SGLT-mediated and cAMP-dependent. Therefore glucagon receptors present in the proximal tubule may display a cellular signalling pathway that is distinct from what is expressed in more distal nephron segments, and which is not coupled primarily to adenylate cyclase and cAMP generation. Future studies are necessary to characterize the signal transduction pathway of these proximal tubule glucagon receptors.
